Ross Douglas T.
Known title: Chief Scientific OfficerCIK: 0001808413
Ross Douglas T.'s purchase track record
Ross Douglas T. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/25/2022 | IMDX | $21K | -27.1% | -42.9% | -18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMDX | ▲ Buy | Grant | 213,797 | $0 | 12/21/2022 | View on chart |
| IMDX | ▼ Sell | Other | 150,000 | $0 | 12/1/2022 | View on chart |
| IMDX | ▲ Buy | Grant | 150,000 | $0 | 8/15/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 15,000 | $21K | 3/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.